Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

BACKGROUND: Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Lattanzi, Michael, Han, Joseph, Moran, Una, Utter, Kierstin, Tchack, Jeremy, Sabado, Rachel Lubong, Berman, Russell, Shapiro, Richard, Huang, Hsin-Hui, Osman, Iman, Bhardwaj, Nina, Pavlick, Anna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958403/
https://www.ncbi.nlm.nih.gov/pubmed/29773080
http://dx.doi.org/10.1186/s40425-018-0345-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958403/
https://www.ncbi.nlm.nih.gov/pubmed/29773080
http://dx.doi.org/10.1186/s40425-018-0345-7

Ejemplares similares